RxCelerate acquires cutting-edge molecular modelling company Prosarix
Summary
RxCelerate has acquired UK-based molecular modelling company Prosarix. The deal expands RxCelerate’s outsourced drug discovery platform with proprietary in silico design and protein engineering capabilities. RxCelerate says the acquisition strengthens its end-to-end service offering for clients that outsource drug discovery and development. Prosarix brings an established customer base and a long track record in molecular modelling for biotech and pharma projects.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected